Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.74 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | ABAT | P80404 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL112119 | 0.92 | — | — | |
| Iodide SCHEMBL28970937 | 0.89 | TAAR1 (0.59) | HRH3TAAR1HTR2ALOXL2ALDH1A1 | |
| Bromide SCHEMBL29023877 | 0.89 | TAAR1 (0.59) | HRH3TAAR1HTR2ALOXL2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL161528 | 0.89 | TAAR1 (0.59) | HRH3TAAR1HTR2ALOXL2ALDH1A1 | |
| Methane SCHEMBL10520385 | 0.89 | TAAR1 (0.59) | HRH3TAAR1HTR2ALOXL2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28560181 | 0.86 | TAAR1 (0.56) | HRH3TAAR1HTR2ALOXL2ALDH1A1 | |
| SCHEMBL2274647 | 0.86 | HRH3 (1.00) | HRH3TAAR1LOXL2CYP2A6ADRB2 | |
| SCHEMBL29288733 | 0.84 | ADRB2 (0.53) | HRH3TAAR1HTR2ALOXL2ALDH1A1 | |
| SCHEMBL3720764 | 0.83 | TAAR1 (0.54) | HRH3TAAR1LOXL2ALDH1A1MAPK1 | |
| SCHEMBL28384280 | 0.82 | TAAR1 (0.52) | HRH3TAAR1HTR2ALOXL2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109330-B2 | Purine inhibitors of cyclin dependent kinase 2 and IκB-α | CV THERAPEUTICS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1150982-B1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkB-alpha | CV THERAPEUTICS INC (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-1021186-B1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkappaB-alpha | CV THERAPEUTICS INC (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20050080261-A1 | Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha | LUM ROBERT T (US) | 2005-04-14 | — | — | US | disclosed |
| CN-1353713-A | Purine inhibitors of cyclin dependent kinase 2 and IK B-alpha | CV THERAPEUTICS INC (US) | 2002-06-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080261-A1 | Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha | IKBKB, NFKB1, CDK4 | HRH3 635/4885TAAR1 2978/4885HTR2A 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.